Paper Details

  1. Home
  2. Paper Details

Interacting medication use and the treatment effects of apixaban versus warfarin: results from the ARISTOTLE Trial.

Author: , AlexanderJohn H, GershBernard J, GrangerChristopher B, HannaMichael, HohnloserStefan H, HorowitzJohn, HylekElaine M, LopesRenato D, VerheugtFreek W A, VinereanuDragos, WallentinLars, WashamJeffrey B, WojdylaDaniel M, XavierDenis

Clinical Trial, Phase IIIA Phase III trial is a trial that further rigorously verifies the efficacy and safety of a new drug or treatment, whose efficacy and safety have been confirmed in a Phase II trial, in a large number of patients, and evaluates whether it is superior to existing treatments.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.

Overview

Interacting medications did not significantly affect the efficacy or safety of apixaban compared to warfarin in patients with atrial fibrillation.
Paper Details　
Original Abstract of the Article :
Warfarin is dependent on multiple hepatic enzymes for metabolism while apixaban is a substrate for P-glycoprotein (P-gp) transport and hepatic CYP3A4 metabolism. The aim of this analysis was to assess the impact of interacting medication use on the treatment effects of apixaban versus warfarin. Outc...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1007/s11239-019-01823-y

データ提供：米国国立医学図書館（NLM）

The Interplay of Medications: Apixaban vs. Warfarin in the Treatment of Atrial Fibrillation

The treatment of atrial fibrillation, a common heart rhythm disorder, often involves anticoagulants to prevent blood clots. This study investigates the impact of interacting medications on the efficacy and safety of two popular anticoagulants: apixaban and warfarin. The researchers utilized data from the ARISTOTLE trial to compare the effects of these medications in patients taking interacting medications, which can potentially alter drug metabolism.

No Significant Impact of Interacting Medications on Treatment Outcomes

The study found no significant differences in the treatment effect of apixaban compared to warfarin, regardless of whether patients were taking interacting medications. This finding suggests that interacting medications do not significantly alter the efficacy or safety of these anticoagulants in patients with atrial fibrillation. However, it's important to note that this study focused on a specific population and may not be generalizable to all patients with atrial fibrillation.

Navigating the Complex World of Medication Interactions

The study highlights the importance of understanding potential medication interactions in the treatment of atrial fibrillation. It emphasizes the need for careful medication management and close monitoring to ensure the safety and efficacy of anticoagulant therapy. Patients with atrial fibrillation should discuss potential interactions with their healthcare providers to ensure they receive the most appropriate treatment for their individual needs.

Dr.Camel's Conclusion

This study provides valuable insights into the complex world of medication interactions. It's like navigating a sandstorm in the desert, where the right combination of medications is crucial for safe and effective treatment. While this study suggests that interacting medications may not significantly alter the efficacy of apixaban and warfarin, it's crucial to remain vigilant and consult with healthcare providers for personalized guidance in managing medication interactions.

Date :
  1. Date Completed 2019-07-22
  2. Date Revised 2020-02-25
Further Info :

Pubmed ID

30790160

DOI: Digital Object Identifier

10.1007/s11239-019-01823-y

SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.